MedTrace Logo

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

NCT04147338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2025-02-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

Guselkumab

Guselkumab will be administered subcutaneously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2021-09-13
Completion
2021-12-07
FDA Drug
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04147338 on ClinicalTrials.gov